Ilayda Korkmaz

Ilayda Korkmaz

Auto-generated profile, based on publicly available information

Ilayda Korkmaz

Ege University Faculty of Medicine, Department of Ophthalmology, İzmir, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2024 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
IKİlayda Korkmaz
İlayda Korkmaz
NENihat Furkan Eratılgan
Nihat Furkan Eratılgan
MPMelis Palamar
Melis Palamar
SESait Eğrilmez
Sait Eğrilmez
AYAyşe Yağcı
Ayşe Yağcı
OSOzlem Barut Selver
Ozlem Barut Selver
Evaluation of Medically Reversible Limbal Stem Cell Deficiency - Turkish Journal of Ophthalmology


23 November 2022 in Eye
Verified
Journal Article
Open access
PDF file
MKMurat KAŞIKCI
Murat KAŞIKCI
IKIlayda Korkmaz
Ilayda Korkmaz
MPMelis Palamar
Melis Palamar
SESait Egrilmez
Sait Egrilmez
AYAyse Yagci
Ayse Yagci
OSOzlem Barut Selver
Ozlem Barut Selver
Objective To evaluate the surgical results and the variables affecting the outcomes in conjunctival-limbal allograft transplantation (CLAL). Methods Patients who underwent CLAL for limbal stem cell deficiency (LSCD) between 2007 and 2019 were included in the study. LSCD staging was performed according to the staging system developed by the ‘Limbal Stem Cell Working Group’. Stage 1C and higher stage LSCD patients were included in the study. ‘Successful surgical outcome’ was defined as improvement in LSCD stage at 1 year postoperatively. Results A total of 19 eyes of 19 LSCD patients were included. The mean age of the patients was 40.21 ± 14.65 (6–65) years, and the male/female ratio was 12/7. CLAL was performed in 9 (47.3%) patients with Stage 2B, 9 (47.3%) patients with Stage 3 and 1 (5.4%) with Stage 1C. LSCD aetiology; chemical injury (12), vernal keratoconjunctivitis (2), aniridia (1), corneal degeneration (1), and unknown (3). Surgery was successful in 52.6% of cases. Surgical success was associated with lower LSCD stage (p = 0.04). Lower grades of chemical injury at presentation and a longer time interval between injury and CLAL were associated with higher surgical success (p = 0.001; p = 0.001). The mean postoperative follow-up time was 50.77 ± 29.46 (6–98) months. Conclusions Despite graft rejection and long-term use of immunosuppressants, CLAL is still one of the most preferred techniques in the treatment of bilateral LSCD. Preoperative LSCD stage and degree of chemical burn are important factors affecting the surgical outcome. Also, CLAL surgery should not be rushed and should be performed when inflammation has subsided.

1 April 2023 in Turkish Journal of Ophthalmology
Verified
Journal Article
Open access
MÇMukaddes Damla Çiftçi
Mukaddes Damla Çiftçi
IKİlAyda Korkmaz
İlAyda Korkmaz
MPMelis Palamar
Melis Palamar
BYBanu Yaman
Banu Yaman
SESait Eğrilmez
Sait Eğrilmez
OSOzlem Barut Selver
Ozlem Barut Selver
Oküler Skatrisyel Pemfigoide Yaklaşım

1 December 2023 in Journal of Ocular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
IKIlayda Korkmaz
Ilayda Korkmaz
MBMine Esen Baris
Mine Esen Baris
SYSuzan Guven Yilmaz
Suzan Guven Yilmaz
MPMelis Palamar
Melis Palamar
Purpose: To evaluate the effects of topical cyclopentolate hydrochloride-induced cycloplegia on anterior segment biomechanics in emmetropic eyes using anterior segment-optical coherence tomography (AS-OCT). Methods: Twenty-five emmetropic eyes of 25 volunteers were included. All underwent central corneal thickness (CCT) and anterior chamber depth (ACD) measurements. Anterior scleral thickness (AST) was measured at the level of the scleral spur (SS)(AST-0), 1,000 μm posterior of the SS (AST-1), and 2,000 μm posterior of the SS (AST-2) in the nasal and temporal quadrants using AS-OCT. All measurements were repeated after cycloplegia. Results: The mean age was 30.6 ± 12.4 (8–45) years. The mean CCT did not significantly change after cycloplegia (P = 0.7). The mean ACD was significantly increased [3.3 ± 0.2 (2.7–3.9) to 3.7 ± 0.3 (3–4.2) μm; P = 0.001]. In the nasal quadrant, the mean AST-1 and AST-2 were 512.3 ± 34.4 (433–570) and 529.6 ± 34.2 (449–599); decreased to 478 ± 26.8 (423–530) and 486.2 ± 28.3 (422–544) μm, respectively, after cycloplegia (P = 0.00; P = 0.00). In the temporal quadrant, the mean AST-1 and AST-2 were 522.5 ± 24.7 (473–578) and 527.2 ± 39.9 (450–604); decreased to 481.1 ± 33.7 (421–550) and 484.6 ± 26.6 (433–528) μm, respectively (P = 0.00; P = 0.00). There was no significant difference in AST-0 after cycloplegia in both quadrants [from 697.5 ± 46 (605–785) to 709.5 ± 64.7 (565–785) for nasal and from 718.4 ± 40.1 (632–796) to 722.9 ± 60.6 (596–838) for temporal; P = 0.2; P = 0.3, respectively]. Conclusion: After cycloplegia, there was a significant thinning of ASTs posterior to SS and a slight increase in AST in the SS level. ACD deepened after cycloplegia, and there was no significant change in CCT. Cycloplegic agents temporarily inhibit ciliary muscle contraction and may affect anterior segment parameters and sclera. Inhibition of forward–inward movement of the ciliary body by cycloplegia affects ASTs and ACD by causing a change in the mechanical force of the ciliary muscle on the sclera.

13 May 2023 in Graefe's Archive for Clinical and Experimental Ophthalmology
Verified
Journal Article
Closed access
PDF file
IKIlayda Korkmaz
Ilayda Korkmaz
CDCumali Degirmenci
Cumali Degirmenci
OSOzlem Barut Selver
Ozlem Barut Selver
MPMelis Palamar
Melis Palamar